EGFR and non-small cell lung carcinoma: To our knowledge, it was the first report of first-line osimertinib-resistant NSCLC with LM harboring EGFR C797S/SM responding to erotinib combined with bevacizumab and chemotherapy and showed significant improved for the patient.